MedTrace Logo

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures

NCT07145346 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-12-08

No results posted yet for this study

Summary

Rib fractures cause a significant amount of pain and are associated with an increased risk of lung infections, long hospitalization, and increased cost. Effective pain control is the cornerstone of management to improve lung function and minimize complications. Most often this is done with a multimodal pain routine consisting of: acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), topical lidocaine, muscle relaxants, and opioids. However, suzetrigine is a promising alternative to treat acute pain associated with rib fractures. We think the addition of suzetrigine to a multimodal pain regimen will improve pain and decrease opioid use.

Conditions

  • Rib Fractures

Interventions

DRUG

Suzetrigine (SUZ)

The intervention arm will receive oral suzetrigine (100 mg loading dose followed by 50 mg every 12 hours).

DRUG

Placebo

The control arm will receive placebo capsules matched to suzetrigine for oral administration.

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-13
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07145346 on ClinicalTrials.gov